

ASX Announcement 23 May 2023

Cogstate Limited ABN 80 090 975 723

Level 2 161 Collins Street Melbourne, Vic, 3000 Australia

P +61 3 9664 1300 F +61 3 9664 1301 W cogstate.com

Amended Change of Director's Interest Notice

Cogstate Ltd (ASX:CGS) notes that a Change of Director's Interest Notice for Mr Richard Mohs ("Notice") was released to the ASX on 22 May 2023.

The Notice had the incorrect 'Date of Change' stated, with the correct date being 16 May 2023.

Please find attached an Amended Notice, reflecting the correct date of 16 May 2023.

Regards
David Franks
Joint Company Secretary

This announcement has been approved for release by Mr Brad O'Connor (Chief Executive Officer) on behalf of the Board of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com

Rule 3.19A.2

AMENDED Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Cogstate Limited
ABN	80 090 975 723

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	RICHARD MOHS
Date of last notice	29 AUGUST 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	DIRECT
Nature of indirect interest (including registered holder)	N/A
Date of change	16 MARCH 2023 16 MAY 2023
No. of securities held prior to change	55,000 - ORDINARY SHARES
Class	ORDINARY SHARES
Number acquired	12,000 - ORDINARY SHARES THROUGH OTC MARKET (TICKER: COGZF)
Number disposed	NIL
Value/Consideration	USD\$1.15 PER ORDINARY SHARE THROUGH OTC MARKET (TICKER COGZF) (USD\$13,800 IN TOTAL). USING SPOT EXCHANGE RATE OF 0.667, THIS IS EQUIVALENT IN AUD OF \$1.72 PER ORDINARY SHARE THROUGH OTC MARKET (TICKER COGZF) (\$20,640 IN TOTAL).
No. of securities held after change	67,000 - ORDINARY SHARES (BEING 55,000 HELD PREVIOUSLY AND EQUIVALENT OF 12,000 ORDINARY SHARES THROUGH OTC MARKET (TICKER COGZF)
Nature of change	ON MARKET ACQUISITION, THROUGH OTC MARKET (TICKER COGZF)

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A

⁺ See <u>chapter 19</u> for defined terms.

01/01/2011 Appendix 3Y Page 1

Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - *Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See <u>chapter 19</u> for defined terms. 01/01/2011 Appendix 3Y Page 2